| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
We have established human immunized mice model by implantation of human peripheral blood mononuclear cells after total irradiation in immunodeficient NOD/SCID/JAK3 null mice, which exhibits a chimera state with predominant human and minor mouse immune cells. We have also established the human immunized mice harboring human biliary tract cancer. We constructed the open-reading frames of several tumor-associated antigen genes as TAA-expression plasmids, and formed DNA vaccine encapsulating the TAA and adjuvant (GM-CSF and CD40L) expression plasmids with nano-sized block/homo-polymer micelles. In the human immunized mice with biliary tract cancer, DNA vaccine expressing TAA-X and adjuvant genes exhibited a significant therapeutic effect. We are on going to identify the mechanism for the induction of TAA-X-specific rejection immunity.
|
